Clinical

Clinical  ·  Weekly Digest - 06 December to 12 December 2025
DESTINY-Ovarian01 Phase 3 Trial of ENHERTU initiated as first-line maintenance therapy in patients with HER2 expressing advanced ovarian cancer

Weekly Digest – December 2025 Weekly Digest – December 2025 09 December 2025: DESTINY-Ovarian01 Phase 3 Trial of ENHERTU initiated as first-line maintenance therapy in patients with HER2 expressing advanced ovarian cancer The DESTINY-Ovarian01 Phase 3 trial has reached a […]

by Sandhya Ramalingam

Continue Reading
Clinical  ·  Weekly Digest - 06 December to 12 December 2025
Biohaven presents clinical safety and efficacy data for BHV-1510, a next-generation Trop2 ADC in combination with cemiplimab at the 2025 ESMO Immuno-Oncology Congress

Weekly Digest – December 2025 Weekly Digest – December 2025 11 December 2025: Biohaven presents clinical safety and efficacy data for BHV-1510, a next-generation Trop2 ADC in combination with cemiplimab at the 2025 ESMO Immuno-Oncology Congress Biohaven reported new clinical […]

by Sandhya Ramalingam

Continue Reading